Table 3.
Impact of patient characteristics on survival: multivariable analysis
| PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
|
p Value |
HR |
95.0% CI |
p Value |
HR |
95.0% CI | |||
| Lower | Upper | Lower | Upper | |||||
| Gender (Female) | 0.02 | 0.28 | 0.10 | 0.80 | 0.49 | 0.69 | 0.24 | 1.98 |
| Age (<60yrs) | 0.17 | 0.62 | 0.31 | 1.23 | 0.20 | 0.61 | 0.28 | 1.30 |
| Lymph node station (Single) | 0.48 | 0.67 | 0.22 | 2.06 | 0.43 | 1.58 | 0.51 | 4.94 |
| Visceral metastasis | 0.35 | 1.86 | 0.51 | 6.77 | 0.66 | 1.35 | 0.36 | 5.06 |
| Without radiation | 0.48 | 1.59 | 0.44 | 5.68 | 0.87 | 1.12 | 0.28 | 4.40 |
| TPN treatment (SD and PD vs PR) | / | / | / | / | 0.03 | 2.32 | 1.06 | 5.05 |
PFS, progression free survival; OS, overall survival; TPN, nimotuzumab with paclitaxel and cisplatin treatment; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio.